Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I/II Study, Single Arm, Open Label, of Protein-Bound Paclitaxel, Cisplatin, and Gemcitabine (GCN) Combined With Tumor Treatment Fields (TTF) in Patient With Metastatic Pancreatic Adenocarcinoma

Summary

The purpose of this phase I/II study is to evaluate the safety and efficacy of Paclitaxel, Cisplatin, and Gemcitabine (GCN) in combination with Tumor Treatment Fields (TTF) in patients with metastatic or recurrent pancreatic cancer.

General Information

NCT#: NCT04605913
Study ID: MC210405
Trial Phase: Phase I/II

Trial Sponsor: Mayo Clinic, NovoCure Ltd.
Therapies Used in This Trial: Gemcitabine, Cisplatin, Paclitaxel

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search